Your browser doesn't support javascript.
loading
Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction.
Thormaehlen, Aenne S; Schuberth, Christian; Won, Hong-Hee; Blattmann, Peter; Joggerst-Thomalla, Brigitte; Theiss, Susanne; Asselta, Rosanna; Duga, Stefano; Merlini, Pier Angelica; Ardissino, Diego; Lander, Eric S; Gabriel, Stacey; Rader, Daniel J; Peloso, Gina M; Pepperkok, Rainer; Kathiresan, Sekar; Runz, Heiko.
Affiliation
  • Thormaehlen AS; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany.
  • Schuberth C; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany.
  • Won HH; Center of Human Genetic Research (CHGR), Massachusetts General Hospital, Boston, Massachusetts, United States of America; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, Uni
  • Blattmann P; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany; Cell Biology/Biophysics Unit, European Molecular Biological Laboratory, Heidelberg, Germany.
  • Joggerst-Thomalla B; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany.
  • Theiss S; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Asselta R; Humanitas University, Milan, Italy.
  • Duga S; Humanitas University, Milan, Italy.
  • Merlini PA; Division of Cardiology, Ospedale Niguarda, Milan, Italy.
  • Ardissino D; Department of Cardiology, Parma Hospital, Parma, Italy.
  • Lander ES; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
  • Gabriel S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
  • Rader DJ; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Peloso GM; Center of Human Genetic Research (CHGR), Massachusetts General Hospital, Boston, Massachusetts, United States of America; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
  • Pepperkok R; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany; Cell Biology/Biophysics Unit, European Molecular Biological Laboratory, Heidelberg, Germany.
  • Kathiresan S; Center of Human Genetic Research (CHGR), Massachusetts General Hospital, Boston, Massachusetts, United States of America; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, Uni
  • Runz H; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/ EMBL, Heidelberg, Germany; Center of Human Genetic Research (CHGR), Massachusetts General Hospital, Boston, Massachusetts, United States of America; Broad
PLoS Genet ; 11(2): e1004855, 2015 Feb.
Article in En | MEDLINE | ID: mdl-25647241
A fundamental challenge to contemporary genetics is to distinguish rare missense alleles that disrupt protein functions from the majority of alleles neutral on protein activities. High-throughput experimental tools to securely discriminate between disruptive and non-disruptive missense alleles are currently missing. Here we establish a scalable cell-based strategy to profile the biological effects and likely disease relevance of rare missense variants in vitro. We apply this strategy to systematically characterize missense alleles in the low-density lipoprotein receptor (LDLR) gene identified through exome sequencing of 3,235 individuals and exome-chip profiling of 39,186 individuals. Our strategy reliably identifies disruptive missense alleles, and disruptive-allele carriers have higher plasma LDL-cholesterol (LDL-C). Importantly, considering experimental data refined the risk of rare LDLR allele carriers from 4.5- to 25.3-fold for high LDL-C, and from 2.1- to 20-fold for early-onset myocardial infarction. Our study generates proof-of-concept that systematic functional variant profiling may empower rare variant-association studies by orders of magnitude.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, LDL / Genetic Association Studies / Exome / Myocardial Infarction Type of study: Risk_factors_studies Limits: Humans Language: En Journal: PLoS Genet Journal subject: GENETICA Year: 2015 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, LDL / Genetic Association Studies / Exome / Myocardial Infarction Type of study: Risk_factors_studies Limits: Humans Language: En Journal: PLoS Genet Journal subject: GENETICA Year: 2015 Document type: Article Affiliation country: Country of publication: